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Available online 10 November 2015transplantation (uHT) based on 6 routine clinical parameters: hemoglobin, sodium, kidney function by theMod-
iﬁcation of Diet in Renal Disease (MDRD) equation, left ventricle ejection fraction (LVEF), percentage of predicted
peak oxygen consumption (VO2) and VE/VCO2 slope.
Objectives:MECKI score must be generalizable to be considered useful: therefore, its performance was validated
in a new sequence of HF patients.
Methods: Both the development (MECKI-D) and the validation (MECKI-V) cohortswere composed of consecutive
HF patients with LVEF b40% able to perform a symptom-limited cardiopulmonary exercise testing. The CVM or
uHT rates were analyzed at one, two and three years in both cohorts: all patients with a censoring time shorter
than the scheduled follow-up were excluded, while those with events occurring after 1, 2 and 3 years were con-
sidered as censored.
Results:MECKI-D and MECKI-V consisted of 2009 and 992 patients, respectively. MECKI-V patients had a higher
LVEF, higher peak VO2 and lower VE/VCO2 slope, higher prescription of beta-blockers and device therapy: after
the 3-year follow-up, CVM or uHT occurred in 206 (18%) MECKI-D and 44 (13%) MECKI-V patients (p b 0.000),
respectively. MECKI-V AUC values at one, two and three years were 0.81 ± 0.04, 0.76 ± 0.04, and 0.80 ± 0.03,
respectively, not signiﬁcantly different from MECKI-D.
Conclusions:MECKI score preserves its predictive ability in a HF population at a lower risk.Keywords:
Heart failure
Prognosis, score© 2015 Elsevier Ireland Ltd. All rights reserved.1. Introduction
Several predictivemodels of outcome in heart failure (HF) have been
proposed, but few of them have been implemented in the clinical prac-
tice. Showing that a prognostic model predicts outcomes in the devel-
opment data is not sufﬁcient to demonstrate its validity; indeed it
must prove to equally perform in different patient populations with
the same diagnosis [1–2].
In 2012, theMetabolic Exercise test data combinedwith Cardiac and
Kidney Indexes (MECKI) score was suggested, to identify the risk of car-
diovascular mortality (CVM) and urgent heart transplantation (uHT)
[3]: it relies on six variables, hemoglobin (Hb), sodium (Na+), kidney
function by means of the Modiﬁcation of Diet in Renal Disease
(MDRD) equation, left ventricle ejection fraction (LVEF) by echocardi-
ography, percentage of predicted peak oxygen consumption (ppVO2),
and minute ventilation-carbon dioxide production (VE/VCO2) slope.
The MECKI score has not as yet been validated.
Therefore, the present study was designed to validate MECKI score's
prognostic capacity in a new, distinct HF cohort.
2. Methods
2.1. Study population
TwoHF cohortswere considered: a derivation cohort (MECKI-D), ex-
trapolated from the original MECKI score study [3], and a validation co-
hort (MECKI-V). Consecutive HF patients were prospectively recruited:
demographics records, etiology of HF, laboratory, ECG (sinus rhythm
versus atrial ﬁbrillation), echocardiographic, CPET and medical treat-
ment data were collected at enrollment in both MECKI populations. In-
clusion and exclusion criteria were those of the original MECKI study
[3]. Inclusion conditionswere previous or present HF symptoms and for-
mer documentation of left ventricular systolic dysfunction (LVEF b40%),
stable clinical conditions with unchanged medications for at least three
months, ability to perform a symptom-limited CPET, and no major car-
diovascular treatment or intervention scheduled. Exclusion criteria
were history of pulmonary embolism, moderate to severe aortic andmi-
tral stenosis, pericardial disease, severe obstructive lung disease,
exercise-induced angina and signiﬁcant ECG alterations or presence of
any clinical comorbidity interfering with exercise performance. Clinical,
laboratory and echocardiographic data were assessed and calculated,
as previously stated [3]: glomerular ﬁltration rate was calculated as
MDRD by using the following formula: 186.3*(crea)−1.154 *(Age)−0.203
*0.75 for women [4]. The MECKI score was calculated in all patients: it
was computed as follows =10.3464 + (−.0262*ppVO2) + (.0472*VE/
VCO2 slope) + (−.1086* Hb) + (−.0615* Na) + (−.0699*LVFE) +
(−.0136*MDRD).2.2. Cardiopulmonary exercise test
Breath-by-breath analysis of expiratory gases and ventilation was
performed. All CPETs were performed using either an electronically
braked cycle ergometer or a treadmill; as in the original MECKI study
[3], for a proper comparison, peak oxygen consumption (VO2) data
measured on treadmill were reduced by 10% [5]. Ventilatory anaerobic
threshold (VAT) was measured by V-slope analysis of VO2 and VCO2
[6], and it was conﬁrmed by ventilatory equivalents and end-tidal pres-
sures of CO2 and O2: VE/VCO2 slope was calculated as the slope of the
linear relationship between VE and VCO2 from 1 min after the
beginning of loaded exercise to the end of the isocapnic buffering peri-
od. Finally, predicted values of VO2 were calculated as: peak VO2
predicted =(Height-Age) *20 if male, =(Height-Age) *14 if female [6].
2.3. Patient follow-up and prognosis
Patient follow-up was carried out according to the local HF surveil-
lance program, and end points were CVM or uHT in both populations.
Patients who died of non-cardiovascular related causes or those who
underwent non urgent HT were considered as censored at the time of
the event. In agreement with the previous statistical procedure [3], all
patients with a censoring time shorter than the scheduled follow-up
thresholds (i.e. 1, 2 or 3 years) were excluded, while those with events
occurring after those cutoff points were considered as censored.
2.4. Statistical analysis
Categorical variables, such as frequency and percentage, were com-
pared by the chi-square test. Numerical variables were summarized as
means± SD. Student's unpaired t-test was used for group comparisons.
Statistical signiﬁcance was deﬁned as p b 0.05. Survival was estimated
by the product-limit Kaplan–Meier method, and differences between
survival curves were tested with the log-rank χ2 statistic. The ability
of MECKI score to correctly predict the occurrence of events was evalu-
ated by receiver-operating characteristic (ROC) analysis. The equiva-
lence of areas under the ROC curve (AUC) was tested according to
Hanley et al. [5].
All analyses were performed using STATA data analysis and statisti-
cal software STATA/IC 11.1 (STATACorp LP, College Station, TX, USA).
3. Results
Although 2716 systolic HF patients were recruited in the original
study, the MECKI-D consisted of 2009 patients, due to MECKI score
missing records. Records were obtained from 13 and 17 Italian HF cen-
ters for MECKI-D and MECKI-V population, while the enrollment phase
Fig. 1. Kaplan–Meier survival curves of MECKI-D and MECKI-V populations. MECKI-D =
MECKI derivation population. MECKI-V =MECKI validation population.
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from February 2002 to March 2013 for the MECKI-V cohort,
respectively.
Age, BMI,MDRD and LVEFwere higher in theMECKI-V cohort, as the
percentage of patients with ischemic heart disease (IHD), and more pa-
tients were in NYHA I class, and less in NYHA III class (Table 1). A better
exercise gas exchange proﬁlewaswitnessed inMECKI-V patients: at the
same peak respiratory exchange ratio (RER), patients showed a higher
mean peak VO2 and ppVO2, while mean VE/VCO2 slope was reduced.
Beta-blockers, loop diuretics, and anti-aldosteronic drugs were more
prescribed in MECKI-V patients, while digitalis treatment was less rec-
ommended. Finally, more MECKI-V patients had an implantable
cardioverter-deﬁbrillator (ICD) (Table 1). Mean MECKI score was
0.105 ± 0.126 and 0.085 ± 0.101 (p b 0.000) in the MECKI-D and in
the MECKI-V cohort, respectively.
No patient was lost to follow-up, and MECKI-V patients showed a
better 3-year outcome (Fig. 1). According to the organization of the
follow-up, 1756 and 825, 1406 and 591, and 1114 and 350 patients
were evaluated in the MECKI-D and MECKI-V cohorts, respectively, at
one, two and three-year follow-up. A higher percentage of devices
(ICD) and beta-blocker treatment, mean LVEF, peak VO2 and ppVO2,
and reduced VE/VCO2 slope were constantly observed in the MECKI-V
population, as well as a higher percentage of patients in NYHA class I
and a lower percentage of patients in NYHA class III (Table 2). A lower
proportion of digitalis prescription was also constantly reported in the
MECKI-V population,whilemeanMDRD, percentage of patients in atrial
ﬁbrillation (AF) and treatedwith amiodaronewas lower in theMECKI-V
cohort at one and two-year follow-up (Table 2). Survival was higher in
MECKI-V vs MECKI-D cohort at all follow-up stages: study endpoints
were registered in 83 (5%) vs 18 (2%) at one year (p = 0.001), 152
(11%) vs 30 (5%) at two years (p b 0.000) and 205 (18%) vs 44 (13%)Table 1
Patients' demographic, HF etiology and disease-related characteristics, medical and device
therapy of the MECKI-D and MECKI-V cohorts.
Number of patients MECKI-D p MECKI-V
2009 992
Males (%) 1681 (84%) 0.673 824 (84%)
Age (years) 61 ± 12 0.021 62 ± 11
Body mass index (kg/m2) 25.6 ± 4 0.011 27.0 ± 4
Ischemic dilated cardiomyopathy (%) 975 (49%) 0.038 522 (53%)
NYHA class I (%) 194 (10%) 0.000 205 (21%)
NYHA class II (%) 1147 (57%) 0.152 539 (54%)
NYHA class III (%) 668 (33%) 0.000 248 (25%)
Atrial Fibrillation (%) 347 (17%) 0.014 136 (14%)
Implanted cardioverter deﬁbrillator (%) 376 (19%) 0.000 418 (44%)
Angiotensin II receptor blockers (%) 332 (17%) 0.266 179 (18%)
Beta-blockers (%) 1578 (79%) 0.000 888 (90%)
Loop diuretics (%) 1603 (80%) 0.017 826 (83%)
Anti-aldosteronic drugs (%) 1048 (52%) 0.023 560 (57%)
Digoxin (%) 577 (29%) 0.000 97 (10%)
Amiodaron (%) 527 (26%) 0.550 247 (25%)
LVEF (%) 31 ± 8.9 0.000 33 ± 10.6
Hb (g/dL) 13.5 ± 1.6 0.501 13.6 ± 1.6
Na+ (mmol/L) 139 ± 3.4 0.471 139 ± 3.2
Crea (mg/dL) 1.21 ± 0.40 0.123 1.18 ± 0.58
MDRD (mL/min) 69.3 ± 22 0.000 72.9 ± 25
Peak VO2 (mL/kg/min) 14.2 ± 4.4 0.000 15.4 ± 4.7
Peak VO2 (% of pred) 52.2 ± 15.5 0.000 58.7 ± 16.3
Peak RER 1.12 ± 0.12 0.121 1.11 ± 0.13
VO2 at VAT (mL/kg/min)⁎ 9.9 ± 3.1 0.000 10.4 ± 3.2
VE/VCO2 slope 33.0 ± 7.6 0.000 31.9 ± 7.2
MECKI score 0.105 ± 0.126 0.000 0.085 ± 0.101
Abbreviations: MECKI =Metabolic Exercise test data combined with Cardiac and Kidney In-
dexes, MECKI-D=MECKI derivation cohort, MECKI-V=MECKI validation cohort, NYHA=
NewYorkHeart Association. LVEF= left ventricular ejection fraction. HB= serumhemoglo-
bin, Na = serum sodium, Crea = serum creatinine, MDRD=Modiﬁcation of Diet in Renal
Disease, VO2 = oxygen consumption, RER = respiratory exchange ratio, VAT =
ventilatory anaerobic threshold.
⁎ When VAT has been identiﬁed.at three years (p b 0.000), respectively. Of note, uHT was witnessed in
17, 29 and 43 patients, and 1, 4 and 4 patients, at one, two and three-
year follow-up in MECKI-D and MECKI-V populations, respectively
(NS). ROC curves AUC values of the MECKI-V cohort were similar
those obtained in the MECKI-D, at the same follow-up period
(Table 3), and ROC curves of the MECKI-V population are shown in
Fig. 2.
4. Discussion
4.1. Study ﬁndings
The predictive power of MECKI score is evident in a HF population,
with a better clinical, medical treatment and exercise proﬁle, and a
lower yearly event rate. This positive validation, together with the sim-
plicity of MECKI score calculation, favors its utilization in daily HF rou-
tine practice.
4.2. Validation of a risk model
The performance of a risk score is typically overestimated in the
original data [1], so validation is a crucial step to provide evidence
about the performance in a different cohort [7]. Three validation strate-
gies are recommended, separate or combined: internal, temporal and
external validation [2]. Internal validation requires splitting the dataset
randomly in two parts, developing themodel using theﬁrst portion, and
then verifying its predictive accuracy in the second portion: this ap-
proach tends to give optimistic results because the two datasets are
very similar. In temporal validation, the model is tested on subsequent
patients from the same center(s) [8–9]: temporal validation is a pro-
spective assessment, independent of the original dataset and develop-
ment process, and it is considered external in time [2]. External
validation uses new data collected from a similar patient population
gathered in a different center: fundamental design issues for external
validation are sample selection and sample size [10–11].
4.3. Validation of a risk model in HF based on CPET data
Several CPET-based risk models have been recommended [12–16],
mostly without validation. Myers et al. [15] developed a risk score
based on 5 CPET variables — VE/VCO2 slope, oxygen uptake efﬁciency
slope, resting end-tidal CO2 pressure (PET-CO2), heart rate (HR) recov-
ery, and peak VO2 — to predict death, cardiac-related hospitalizations,
HT, and left ventricular assist device (LVAD) implantation in HF pa-
tients. The optimal threshold was identiﬁed for each variable, then a
“weighted” risk was assigned according to the hazard ratios: the
resulting single-variable scores were summed to obtain the composite
multivariable score. A summed score N 15was associatedwith an annu-
al mortality rate of 27%, whereas a score b 5 was associated with a mor-
tality rate of 0.4% [14]. Myers's CPET risk model was validated in 2625
Table 2
Patients' demographic, HF etiology and disease-related characteristics, medical and device therapy of the MECKI-D and MECKI-V cohorts at one, two and three years follow up.
1 Yr 2 Yrs 3 Yrs
MECKI-D p MECKI-V MECKI-D p MECKI-V MECKI-D p MECKI-V
Number of patients 1756 825 1406 591 1114 350
Males (%) 1467(84%) 0.864 687(84%) 1178(84%) 0.790 498(84%) 932 (84%) 0.864 295 (84%)
Age (years) 61.2 ± 12.2 0.051 62.2 ± 12.1 61 ± 12 0.021 62.5 ± 12 61 ± 12 0.003 63 ± 11
Body mass index (kg/m2) 26.6 ± 4.3 0.059 26.9 ± 4.4 26.5 ± 4.4 0.228 26.8 ± 4.3 26.4 ± 4 0.591 26.7 ± 4
Ischemic dilated cardiomyopathy (%) 864(49%) 0.481 431(52%) 691(49%) 0.489 305(51%) 560 (50%) 0.451 184 (53%)
NYHA class I (%) 168(10%) 0.000 164(20%) 133(9%) 0.000 111(19%) 105 (9%) 0.000 64 (18%)
NYHA class II (%) 1021(58%) 0.332 463(56%) 822(58%) 0.915 344(58%) 652 (59%) 0.332 205 (59%)
NYHA class III (%) 567(32%) 0.000 198(24%) 451(32%) 0.000 136(23%) 357 (32%) 0.002 81 (23%)
Atrial Fibrillation (%) 313(18%) 0.001 105(13%) 252(18%) 0.001 70(12%) 193 (17%) 0.001 47 (13%)
Implanted cardioverter deﬁbrillator (%) 327(19%) 0.000 351(45%) 238(17%) 0.000 241(44%) 170 (15%) 0.000 151 (46%)
Angiotensin II receptor blockers (%) 288(16%) 0.519 143(17%) 227(16) 0.983 95(16%) 171 (15%) 0519 61 (18%)
Beta-blockers (%) 1365(78%) 0.000 737(90%) 1075(76%) 0.000 525(89%) 845 (76%) 0.000 316 (91%)
Loop diuretics (%) 1414(81%) 0.085 686(83%) 1147(82%) 0.444 489(83%) 936 (84%) 0.085 299 (86%)
Anti-aldosteronic drugs (%) 916(52%) 0.016 471(57%) 725(52%) 0.050 332(56%) 565 (51%) 0.076 196 (56%)
Digoxin (%) 542(31%) 0.000 81(10%) 475(34%) 0.000 56(10%) 411 (37%) 0.000 39 (11%)
Amiodaron (%) 476(27%) 0.073 195(24%) 380(27%) 0.010 126(21%) 294 (26%) 0.073 75 (21%)
LVEF (%) 31. ±8.9 0.000 32.6 ± 10.9 30.8 ± 8.9 0.000 32.7 ± 11.3 30 ± 8.8 0.000 33 ± 11.2
Hb (g/dL) 13.5 ± 1.6 0.817 13.5 ± 1.6 13.5 ± 1.6 0.503 13.5 ± 1.6 13.5 ± 1.6 0.817 13.6 ± 1.6
Na+ (mmol/L) 139.5 ± 3.5 0.308 139.4 ± 3.1 139.4 ± 3.5 0.637 139 ± 3.2 139 ± 3.6 0.308 139 ± 3.3
Crea (mg/dL) 1.2 ± .4 0.229 1.18 ± .6 1.2 ± .39 0.638 1.19 ± .66 1.21 ± 0.40 0.229 1.23 ± 0.78
MDRD (mL/min) 69.4 ± 22 0.000 72.9 ± 23.8 69.4 ± 22.2 0.002 72.8 ± 23.5 69.5 ± 22 0.770 68.7 ± 24
Peak VO2 (mL/kg/min) 14.2 ± 4.3 0.000 15.6 ± 4.8 14.1 ± 4.3 0.000 15.6 ± 4.9 14.2 ± 4.4 0.000 15.4 ± 4.7
Peak VO2 (% of pred) 52.8 ± 15.5 0.000 59 ± 16.4 52.5 ± 15.4 0.000 58.7 ± 16.5 52.2 ± 15.5 0.000 58.0 ± 16.3
Peak RER 1.12 ± .13 0.707 1.12 ± .13 1.11 ± .13 0.320 1.12 ± .13 1.11 ± 0.10 0.707 1.12 ± 0.10
VO2 at VAT (mL/kg/min) 10 ± 3.1 0.001 10.5 ± 3.2 10.1 ± 3.1 0.070 10.4 ± 3.17 10.2 ± 3.1 0.012 10.2 ± 2.7
VE/VCO2 slope 33.1 ± 7.6 0.000 31.9 ± 7.2 33.4 ± 7.6 0.000 31.9 ± 7.1 33.7 ± 7.6 0.000 31.9 ± 7.0
Abbreviations: see Table 1. Yrs = years.
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patients with both impaired and preserved LVEFwere enrolled, and dif-
ferent type of adverse events were taken into account. Again, the
summed risk score predicted outcomes with C indexes 0.70 for cardiac
mortality and 0.72 for major events, respectively, and estimated one-
year death rate of 12.2% in patients with a summed score of N15 and
of 1.2% in those with a summed score b 5 [17].
Exercise variables were included in other prognostic models in HF
[18–20], but only the Heart Failure Survival Score (HFSS) incorporated
peak VO2: this score was evaluated in 268 ambulatory advanced HF pa-
tients (derivation sample), and it was prospectively validated in 199
similar patients [18]: outcome events were death without HT or urgent
HT at 1 year. Freedom fromeventswas signiﬁcantly better in the deriva-
tion group than in the validation group (76 ± 3% versus 68 ± 4% at
1 year and 63 ± 3% versus 51 ± 5% at 2 years, respectively; p b
0.025), and, in the derivation cohort, the event-free survival rates at
1 year for the low, medium, and high-risk HFSS strata were 93 ± 2%,
72 ± 5%, and 43 ± 7%, respectively, while in the validation group they
were 88 ± 4%, 60 ± 6%, and 35 ± 10% in the low, medium, and high-
risk HFSS strata, respectively [18].
The MECKI score was developed in a large HF population,
performing symptom-limited CPET [3]: at multivariable Cox analysis
with subsequent cross validation, includingmore than 35 risk variables,
only Hb, Na+, MDRD, LVEF, ppVO2, and VE/VCO2 slope resultedTable 3
AUC values derived from receiver-operating characteristic (ROC) analysis with 95% interval of
AUC were generated at one, two and three years.
MECKI-D
Patients observed AUC 95% IC
One year 1756 0.80 ± 0.02 0.75–0.85
Two yrs 1418 0.79 ± 0.01 0.75–0.82
Three yrs 1114 0.76 ± 0.01 0.72–0.80
Abbreviations: see Table 1. Yrs = years. AUC = area under the curve, IC: interval of conﬁdenceindependently related to prognosis, and, on the basis of these 6 contin-
uous variables, the MECKI score was deﬁned to identify the risk of CVM
and uHT. Moreover, an internal validation was performed, and a high
concordance was detected between 2-year predicted and observed
risk of event, stratiﬁed by decile of risk. The MECKI score AUC was
0.804 (0.754–0.852) at 1 year (1758 survivors and 83 events), 0.789
(0.750–0.828) at 2 years (1254 survivors and 152 events), 0.762
(0.726–0.799) at 3 years (1114 survivors and 205 events), and 0.760
(0.724–0.796) at 4 years (891 survivors and 246 events). It was con-
cluded that the MECKI score is a simple, reliable, easy to calculate, per-
sonalized HF prognostic tool, with the high AUC values [3]. Albeit few
reports have been generated from the MECKI score database, the
MECKI score has not been validated, yet.
In the present study, the MECKI score model was validated in a new
HFpopulation, combining a temporal and an external conﬁrmation pro-
cess. TheMECKI-V cohort wasmade up of 992 HF patients, prospective-
ly enrolled, with inclusion/exclusion criteria and end-point events
identical to those of the MECKI-D original study. Moreover, the statisti-
cal management of survival and event rate was analogous, as well [3].
MECKI-D andMECKI-V clinical and treatment featureswere signiﬁcant-
ly dissimilar, and, in particular, MECKI-V patients showed a higher LVEF,
ppVO2 and MDRD, and a lower VE/VCO2 slope: accordingly, MECKI
score was meaningfully divergent, lower in MECKI-V population. As
regards outcomes, as expected, a lower occurrence of events wasconﬁdence in MECKI-D and MECKI-V cohorts.
MECKI-V
Patients observed AUC 95% IC p AUC values
825 0.81 ± 0.04 0.73–0.89 0.11
597 0.76 ± 0.04 0.68–0.84 0.29
350 0.80 ± 0.03 0.73–0.86 1.05
.
Fig. 2. Receiver-operating characteristic (ROC) analysis of the MECKI score at 1, 2, and
3 years for patients enrolled in the MECKI-V cohort. For abbreviations, see Table 3.
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thresholds. Nonetheless, theMECKI score retained the predictive capac-
ity to identify patients at risk of coming events. The AUC values generat-
ed byROC analysis were good in theMECKI-V cohort at different follow-
up closures, comparable to those observed in the MECKI-D cohort [3].4.4. Limitations
At least two constraints should be mentioned. Due to technical mo-
tivations, i.e. the enrollment phase of MECKI-V, the sample size and the
number of events observed later on, the follow up analysis was reduced
to 3 years, so that a comparative analysis of MECKI score in MECKI-D
and MECKI-V populations at 4 years was precluded. Moreover, MECKI
score was validated to identify patients at risk, applying standard out-
come events: different end points, such as LVAD implantation and
cardiac-related hospitalizations, might have provided different results.
4.5. Conclusions
Guidance in efﬁcient clinical decision-making requires accurate risk
assessment; unfortunately, the paucity of validation studies justiﬁes cli-
nicians in not always trusting the probabilities provided by new risk
models. The validation of MECKI score, together with the simplicity of
the model with easy available measurements, legitimates its employ-
ment in daily HF routine as a prognostic tool.
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